Edition:
United States

Sinovac Biotech Ltd (SVA.O)

SVA.O on Nasdaq

7.06USD
23 Oct 2017
Change (% chg)

-- (--)
Prev Close
$7.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
122,847
52-wk High
$7.16
52-wk Low
$4.60

Latest Key Developments (Source: Significant Developments)

Sinobioway Consortium provides update on acquiring Sinovac Biotech at $8 per share
Friday, 29 Sep 2017 08:00am EDT 

Sept 29 (Reuters) - Sinovac Biotech Ltd :Sinobioway Consortium provides update on acquiring Sinovac Biotech (Nasdaq: SVA) at the purchase price of $8 per share.Shandong Sinobioway Biomedicine-deal to be funded by offshore US dollars not subject to relevant governmental approval or foreign exchange supervision​.Shandong Sinobioway Biomedicine says Sinobioway Consortium has sent all new documents required by special committee in September 1​.  Full Article

Sinovac Biotech preliminary phase III data shows Varicella vaccine was 87.1 pct efficacious against Chickenpox ​
Monday, 25 Sep 2017 06:00am EDT 

Sept 25 (Reuters) - Sinovac Biotech Ltd :Sinovac reports preliminary top-line results from phase III clinical trial for Varicella vaccine candidate against Chickenpox.Sinovac Biotech - ‍Preliminary phase III data showed that Sinovac's Varicella vaccine was 87.1% efficacious against chickenpox caused by vzv​.Sinovac Biotech Ltd - ‍On track for Sinovac commercialization by end of 2019​.  Full Article

Sinobioway consortium provides update on Sinovac Biotech acquisition
Thursday, 10 Aug 2017 06:42am EDT 

Aug 10 (Reuters) - Sinovac Biotech Ltd :Sinobioway consortium provides update on acquiring Sinovac Biotech at the purchase price of $8 per share.Shandong Sinobioway Biomedicine​ - ‍Sinobioway consortium submitted "restate offer" at $8/share to Sinovac's board and special committee on June 28, 2017.  Full Article

Shandong Sinobioway's consortium makes an offer to take Sinovac Biotech private
Tuesday, 27 Jun 2017 10:08pm EDT 

June 28 (Reuters) - Shandong Sinobioway Biomedicine Co Ltd <002581.SZ>:* Says its consortium offers to buy Sinovac Biotech Ltd at $8 per share to take it private.  Full Article

Sinovac Biotech enters into agreement for going-private transaction
Monday, 26 Jun 2017 09:03am EDT 

June 26 (Reuters) - Sinovac Biotech Ltd ::Sinovac Biotech Ltd enters into definitive agreement for going-private transaction.Sinovac Biotech Ltd - deal for approximately US$401.8 million.Sinovac Biotech Ltd - pursuant to amalgamation agreement, parent will acquire company for cash consideration equal to us$7.00 per common share of company.Sinovac Biotech Ltd says ‍consideration to be paid to holders of shares also represents increase of about 13.3% from original $6.18/share offer price​.Sinovac Biotech Ltd -buyer consortium intends to fund amalgamation through combination of cash contributions from C-Bridge Capital, Advantech Capital, Vivo Capital.Sinovac Biotech Ltd - entered into a definitive amalgamation agreement with Sinovac (Cayman) Limited (parent) and Sinovac Amalgamation Sub Limited.Sinovac Biotech Ltd - board, acting upon unanimous recommendation of special committee formed by board, unanimously approved amalgamation agreement.Sinovac Biotech Ltd - as of June 23, members of buyer consortium beneficially own in aggregate approximately 29.5% of issued and outstanding shares.  Full Article

Sinovac Biotech announced it is delaying its annual report on form 20-F
Tuesday, 16 May 2017 04:08pm EDT 

May 16 (Reuters) - Sinovac Biotech Ltd :Announced it is delaying its annual report on form 20-F for the year ended December 31, 2016 - SEC filing.Sinovac does not expect that it will be able to file the 2016 annual report within the 15-day extension period.Audit committee requires additional time for internal investigation regarding allegations raised in research report by Geoinvesting.Investigation has slowed completion of the company’s financial statements and audit for the year ended December 31, 2016.  Full Article

Sinovac amends shareholder rights plan
Friday, 24 Mar 2017 06:00am EDT 

Sinovac Biotech Ltd : Sinovac amends shareholder rights plan . Sinovac Biotech Ltd - amendment extends expiration date of plan from March 27, 2017 to March 27, 2018 .Sinovac Biotech Ltd - amendment was not in response to any acquisition proposal.  Full Article

Sinovac responds to recent report
Friday, 23 Dec 2016 06:00am EST 

Sinovac Biotech Ltd : Sinovac Biotech - Responded to a recent report regarding allegations raised in a research report by Geoinvesting . Sinovac Biotech - Pending outcome of investigation no legal proceedings or government inquiries have been made against company or its CEO Mr. Yin . Sinovac's audit committee has authorized commencement of an internal investigation into allegations made in report .Audit committee has engaged Latham & Watkins as independent counsel to assist with investigation..  Full Article

Sinovac posts Q2 loss of $0.17/share
Tuesday, 23 Aug 2016 06:00am EDT 

Sinovac Biotech Ltd: Sinovac reports unaudited second quarter 2016 financial results . Q2 loss per share $0.17 . Q2 non-GAAP loss per share $0.15 from continuing operations . Q2 sales $1.4 million versus $18.5 million . Will seek new commercial bank loans to finance commercialization of pipeline products . "Expect that sales in our fiscal second half of year will be much stronger than first half" .Expects that its current cash position will be able to support its operations for next 12 months.  Full Article

Sinovac says Shandong incident had material effect on revenues in Q1
Thursday, 26 May 2016 06:00pm EDT 

Sinovac Biotech Ltd : Shandong incident had a material effect on our revenues in Q1 and we expect that trend will continue into Q2 . Company expects that its current cash position will be able to support its operations for next 12 months . Sinovac reports unaudited first quarter 2016 financial results . Q1 non-gaap loss per share $0.01 from continuing operations . Q1 earnings per share $0.02 .Q1 sales rose 19 percent to $11 million.  Full Article

BRIEF-Sinobioway Consortium provides update on acquiring Sinovac Biotech at $8 per share

* Sinobioway Consortium provides update on acquiring Sinovac Biotech (Nasdaq: SVA) at the purchase price of $8 per share